Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer

Abstract

Presently, surgery is the only treatment approach for gastric cancer and improving the prognosis of locally advanced gastric cancer is one of the key factors in promoting gastric cancer survival benefit. The MAGIC study was the first to demonstrate the efficacy of neoadjuvant chemotherapy (NAC) in European countries. In recent years, several clinical trials have provided evidence for the use of NAC in Asian patients with locally advanced gastric cancer. However, clinical practice guidelines vary between Asian and non-Asian populations. Optimal NAC regimens, proper target populations, and predictors of NAC outcomes in Asian patients are still under investigation. Herein, we summarized the current progress in the administration of NAC in Asian patients with gastric cancer.

The impact of neoadjuvant chemotherapy on the clinical efficacy and serum tumor marker levels in patients undergoing radical surgery for gastric cancer

“…(2) A comparison was made between the 2 groups regarding intraoperative blood loss, surgical duration, surgical margin, number of LNs dissected, postoperative ambulation time, postoperative hospital stay, and postoperative time to passage of flatus. (3) The levels of serum CEA, AFP, CA125, and CA72-4 were compared between the 2 groups. (4) The Karnofsky Performance Status (KPS) scores were compared between the 2 groups.…”

“…Therefore, the medical field has been actively exploring treatment methods to improve the prognosis of GC. [3,4] Neoadjuvant therapy has been used for the treatment of various other cancers, such as non-small cell lung cancer and head and neck cancer. [5,6] Furthermore, the feasibility of neoadjuvant chemotherapy (NAC) for GC is also being actively explored.…”

“…Therefore, the medical field has been actively exploring treatment methods to improve the prognosis of GC. [ 3 , 4 ]…”

Problems of Surgical Treatment of Gastric Malignant Neoplasms Complications

“…Незважаючи на суттєві досягнення у діагностиці та прогнозуванні, перед-, інтра-та післяопераційному веденні, розвитку хірургічної техніки, частота ускладнень після операцій з приводу злоякісних новоутворень (ЗН) шлунка практично не змінюється упродовж останніх років. Показники післяопераційних ускладнень суттєво різняться і досягають залежно від джерела, 20-40 % при лікарняній летальності -10-33 % [5].…”